TACR1 and myeloid leukemia: Taken together, this study revealed antitumor effects of NK-1R antagonists, a class of antiemetic drugs used in conjunction with cancer chemotherapy to treat myeloid leukemia, which provides a therapeutic option for leukemia treatment.